Floatz logo

azd5305

Lung Squamous Cell Carcinoma

AstraZenecaPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Lung Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
Gefetinib
Seoul Veterans Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

azd5305 is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →